Diabetes Care, Vol 9, Issue 2 140-148, Copyright © 1986 by American Diabetes Association

ARTICLES

Veterans Administration Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: II. Effects of aspirin and dipyridamole on atherosclerotic vascular disease rates

JA Colwell, SF Bingham, C Abraira, JW Anderson, JP Comstock, HC Kwaan and F Nuttall

We report the results of a randomized multicenter clinical trial on the effects of aspirin plus dipyridamole versus placebo on major vascular end points in 231 non-insulin-dependent diabetic men with either a recent amputation for gangrene or active gangrene. Primary end points were death from atherosclerotic vascular disease plus amputation of the opposite extremity for gangrene. There were 24 atherosclerotic deaths in the drug treatment group (21.8%) and 23 in the placebo group (19.0%). There were 22 patients in the drug treatment group (20.0%) and 29 patients in the placebo group (24.0%) with opposite-side amputations. Survival curve analyses revealed little difference between these groups for major vascular end points, total mortality, all amputations, or myocardial infarctions. The most noteworthy group difference was observed for cerebrovascular end points (strokes and transient ischemic attacks), with an incidence of 8.2% (9 patients) in the drug treatment group and 19.0% (23 patients) in the placebo group. We conclude from this study that antiplatelet agents have no effect on the primary vascular end points, vascular deaths and/or amputation of the opposite extremity, in this population. Similarly, no effects were seen on secondary vascular end points, except for a suggestion of protection versus strokes and transient ischemic attacks. However, this finding must be interpreted with caution, since it is a secondary end point and was found only after multiple analyses of the data.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				G. G. Neri Serneri, S. Coccheri, E. Marubini, F. Violi, and for the Committees and the Investigators of the Dr Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study Eur. Heart J., October 2, 2004; 25(20): 1845 - 1852. [Abstract] [Full Text] [PDF]

				P J Watkins and P K Thomas Diabetes mellitus and the nervous system J. Neurol. Neurosurg. Psychiatry, November 1, 1998; 65(5): 620 - 632. [Full Text]

				M. Eccles, N. Freemantle, J. Mason, and t. N. o. E. A. G. D. Group North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care BMJ, April 25, 1998; 316(7140): 1303 - 1309. [Full Text]

				J. S Yudkin Which diabetic patients should be taking aspirin? BMJ, September 9, 1995; 311(7006): 641 - 642. [Full Text]

				Antiplatelet Trialists Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ, January 8, 1994; 308(6921): 81 - 106. [Abstract] [Full Text]